{"id":170125,"date":"2025-08-13T08:04:56","date_gmt":"2025-08-13T12:04:56","guid":{"rendered":"https:\/\/44.250.171.167\/?p=170125"},"modified":"2025-08-13T08:04:56","modified_gmt":"2025-08-13T12:04:56","slug":"suven-life-sciences-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/suven-life-sciences-q1-fy26-earnings-results\/","title":{"rendered":"Suven Life Sciences Q1 FY26 Earnings Results"},"content":{"rendered":"<p>Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders. The company has been working towards developing new molecules\/ compounds in the complex CNS (central nervous system) space. Most of its lead molecules address the niche areas of cognitive impairments such as amnesia, dementia, narcolepsy, Alzheimer&#8217;s, delirium, etc. CNS is the 2nd largest therapeutic category in the pharmaceutical industry and is also one of the fastest growing segments.\u00a0Presenting below are its Q1 FY26 earnings results.<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"q1-fy26-earnings-summary-apriljune-2025\" class=\"mb-2 mt-4 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Q1 FY26 Earnings Results<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Net Loss:<\/strong> \u20b952 crore, widening from previous quarters, reflecting ongoing operational challenges.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Revenue:<\/strong> \u20b92 Crore, the company witnessed a 100% plus growth in the YoY basis.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Expenses:<\/strong> \u20b952 Crore, a steep rise of 64%, High operational costs continued to impact profitability.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Margins:<\/strong>\u00a0Negative EBIT and net profit margins persist, indicating challenging profitability.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Earnings Per Share (EPS):<\/strong> \u20b9 -2.37, showing continued losses.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Stock Reaction:<\/strong>\u00a0Shares declined by about 5% after results release.<\/p>\n<\/li>\n<\/ul>\n<h3 id=\"key-management-commentary--strategic-highlights\" class=\"mb-2 mt-4 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">\nKey Management Commentary &amp; Strategic Highlights<\/h3>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Suven Life Sciences highlighted ongoing investment in clinical trials and R&amp;D as core to <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/774615df-d0c7-4863-94cf-5329f3819b82.pdf\" target=\"_blank\" rel=\"noopener\">long-term growth<\/a>, although these continue to weigh on near-term earnings.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">The company is working to expand its contract research and manufacturing services (CRAMS) business, focusing on specialty chemicals and intermediates.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Management remains focused on scaling clinical development partnerships to <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/774615df-d0c7-4863-94cf-5329f3819b82.pdf\" target=\"_blank\" rel=\"noopener\">improve revenue visibility<\/a>.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Cost control measures and operational efficiencies are priorities amid market challenges.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Suven is committed to advancing its pipeline in neuroscience and other specialty segments.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-170126\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-8-839x1024.png\" alt=\"Suven Life Sciences Q1 FY26 Earnings Results\" width=\"640\" height=\"781\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-8-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-8-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-8-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-8-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-8.png 1489w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"q4-fy25-earnings-snapshot-januarymarch-2025\" class=\"mb-2 mt-4 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Q4 FY25 Earnings Results<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li>Suven Life Sciences Ltd reported Revenues for Q4FY25 of \u20b91.00 Crores down from \u20b92.00 Crore year on year, a fall of 50.0%.<\/li>\n<li>Total Expenses for Q4FY25 of \u20b946.00 Crores up from \u20b935.00 Crores year on year, a rise of 31.43%.<\/li>\n<li>Consolidated Net Profit of -\u20b944.00 Crores from -\u20b927.00 Crores in the same quarter of the previous year.<\/li>\n<li>The Earnings per Share is -\u20b92.01, from -\u20b91.22 in the same quarter of the previous year.<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">No significant recovery observed in Q4 FY25 as well.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">The company continues to navigate a difficult market environment with investments in innovation and trials.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>To view the company&#8217;s previous earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/suven\/\">click here<\/a>\u00a0 to visit the Alphastreet India news channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders. The company has been working towards developing new molecules\/ compounds in the complex CNS (central nervous system) space. Most of its lead molecules address the niche areas of cognitive impairments [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":170126,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[3059],"class_list":["post-170125","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-healthcare-stocks","tag-biopharma"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-8.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169131,"url":"https:\/\/alphastreet.com\/india\/suven-life-sciences-ltd-q4fy25-50-fall-in-revenue\/","url_meta":{"origin":170125,"position":0},"title":"Suven Life Sciences Ltd Q4FY25; 50% fall in Revenue","author":"Chirag Gupta","date":"July 14, 2025","format":false,"excerpt":"Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders. Financial Results: Suven Life Sciences Ltd reported Revenues for Q4FY25 of \u20b91.00 Crores down from \u20b92.00 Crore year on year, a fall of 50.0%. Total\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":151736,"url":"https:\/\/alphastreet.com\/india\/suven-life-sciences-ltd-q1fy24-0-equalled-in-revenue\/","url_meta":{"origin":170125,"position":1},"title":"Suven Life Sciences Ltd Q1FY24; 0% equalled in Revenue","author":"Chirag Gupta","date":"August 8, 2023","format":false,"excerpt":"Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders. Financial Results: Suven Life Sciences Ltd reported Revenues for Q1FY24 of \u20b94.00 Crores same from \u20b94.00 Crore year on year. Total Expenses for Q1FY24 of\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-355.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-355.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-355.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-355.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-355.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-355.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":147287,"url":"https:\/\/alphastreet.com\/india\/suven-pharmaceuticals-ltd-q4fy23-results-out-net-profit-grows-by-35\/","url_meta":{"origin":170125,"position":2},"title":"Suven Pharmaceuticals Ltd Q4FY23 results out, net profit grows by 35%","author":"Chirag Gupta","date":"May 25, 2023","format":false,"excerpt":"Suven Pharma is in the business of Contract development & manufacturing organisation (CDMO), catering to the needs of global Pharma Industry. SPL engages in NCE molecule development and supply of intermediates. This is a high-value-add, high-margin business. SPL supplies intermediates for four molecules addressing rheumatoid arthritis, diabetes, depression and women\u2019s\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":157352,"url":"https:\/\/alphastreet.com\/india\/life-sciences-ltd-q2fy24-25-fall-in-revenue\/","url_meta":{"origin":170125,"position":3},"title":"Life Sciences Ltd Q2FY24; 25% fall in Revenue","author":"Chirag Gupta","date":"December 14, 2023","format":false,"excerpt":"Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders. Financial Results: Suven Life Sciences Ltd reported Revenues for Q2FY24 of \u20b93.00 Crores down from \u20b94.00 Crore year on year, a fall of 25.0%. Total\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-111.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-111.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-111.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-111.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-111.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-111.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170679,"url":"https:\/\/alphastreet.com\/india\/kingfa-q1-fy26-earnings-results\/","url_meta":{"origin":170125,"position":4},"title":"Kingfa Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 27, 2025","format":false,"excerpt":"Kingfa Science & Technology (India) Limited, a subsidiary company of M\/s Kingfa Science & Technology Co. Ltd China, is engaged in the business of manufacturing and supply of high-quality modified plastic compounds for automotive and consumer products and personal protective equipments like masks and gloves. Presenting below are its Q1\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Kingfa Sciences & Technology Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-18.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-18.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-18.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-18.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-18.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-18.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":174349,"url":"https:\/\/alphastreet.com\/india\/suven-life-sciences-limited-suven-q1-2026-earnings-call-transcript\/","url_meta":{"origin":170125,"position":5},"title":"Suven Life Sciences Limited (SUVEN) Q1 2026 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Suven Life Sciences Limited (NSE: SUVEN) Q1 2026 Earnings Call dated Aug. 13, 2025 Corporate Participants: Cyndrella Carvalho \u2014 Suven Life Sciences Limited Vivek Sharma \u2014 Executive Chairman Prasada Raju V \u2014 Managing Director Himanshu Agarwal \u2014 Chief Financial Officer Analysts: Avnish Burman \u2014 Analyst Dhawal Khut \u2014 Analyst Harith\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=170125"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170125\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/170126"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=170125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=170125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=170125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}